Browsing Tag
NSCLC
29 posts
Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC
Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib),…
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 “ELUCIDATE” study, marking the first trial…
Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300
Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with…
BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in…
FDA rejects Lilly’s sintilimab as first line treatment of NSCLC
The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and…
AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination…
AstraZeneca wins FDA approval for Tagrisso in adjuvant treatment of early-stage NSCLC patients with EGFR mutations
Find out how AstraZeneca’s expanded FDA approval for Tagrisso is transforming early-stage lung cancer treatment standards.
Pfizer’s Vizimpro receives EMA approval recommendation for NSCLC treatment
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost…
Genprex announces promising results for Oncoprex in Phase II lung cancer trial
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for…